US2006030626A1PendingUtilityA1
Method of treating autoimmune diseases
Est. expiryNov 21, 2020(expired)· nominal 20-yr term from priority
A61P 37/00A61K 31/00A61K 31/407A61K 31/4353A61K 31/222A61K 31/18A61K 31/336A61K 31/165A61K 31/16G01N 2500/04A61K 31/22A61K 31/4406A61K 31/167A61K 31/166A61K 31/473C12Q 1/44A61P 17/14A61K 31/19A61K 31/17A61K 31/70A61K 31/192
48
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method of treating an autoimmune disease comprising administering to the subject a treatment effective amount of a histone hyperacetylating agent, or a pharmaceutically acceptable salt thereof.
Claims
exact text as granted — not AI-modified1 . A method of treating an autoimmune disease in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt thereof.
2 . A method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt thereof.
3 . A method of treating an autoimmune disease in a subject in need thereof, the method comprising administering to the subject a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt thereof in an amount sufficient to treat a symptom of autoimmune disease.
4 . A method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering to said subject a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt thereof in an amount sufficient to treat a symptom of systemic lupus erythematosus.Join the waitlist — get patent alerts
Track US2006030626A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.